Industry News Genetix Biotherapeutics (formerly bluebird bio) BioSpace
Ex-bluebird Genetix says its gene therapies are profitable, guiding to about $500M in 2026
- Genetix, bluebird bio renamed after Carlyle and SK Capital bought it in February 2025, reported $327M of U.S. net sales year to date and guides to about $500M for 2026.
- About 700 patients have been treated since 2022, 326 of them this year; blood-disease sales (Lyfgenia, Zynteglo) are up 95% year on year.
- It says it has been profitable since Q4 2025, and is studying Lyfgenia in children as young as two, with a filing planned to extend use to age 12.
This is the best public proof that an ultra-expensive gene therapy franchise can work once the overhead of a listed biotech is stripped out. Two caveats: figures are self-reported by a private company no longer obliged to disclose, and the contingent value right for old shareholders needs $600M in 12 months, which guidance of $500M does not yet reach. Rivals with sickle cell programs should read it as evidence that demand is real but throughput-limited.
Source: BioSpace ↗ Genetix's genetic medicines are officially profitable, with $327M in sales YTD